within Pharmacolibrary.Drugs.ATC.S;

model S01EE06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 1e-06,
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Latanoprostene bunod is a prostaglandin F2Î± analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is an ophthalmic solution approved for use in adults. The drug is hydrolyzed in the eye to produce two active moieties: latanoprost acid and nitric oxide, both contributing to IOP reduction.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not reported in peer-reviewed publications for latanoprostene bunod in humans. Based on estimated model for topically administered ophthalmic prostaglandin analogs.</p><h4>References</h4><ol><li>Megan E Cavet, Heleen H DeCory,The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.,Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,2018<a href='https://pubmed.ncbi.nlm.nih.gov/28783422/'>https://pubmed.ncbi.nlm.nih.gov/28783422/</a></li><li>Michelle G Pedler, J Mark Petrash, Prem S Subramanian,Prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa.,PloS one,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34971554/'>https://pubmed.ncbi.nlm.nih.gov/34971554/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01EE06;
